Pilatus Biosciences to Present New Preclinical Data Advancing PLT012 into COPD at the European Respiratory Society International Congress 2026
Pilatus Biosciences, a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies to address unmet medical needs in cancer and immune-related diseases, today announced that new preclinical data from PLT012, its lead first-in-class CD36-targeting monoclonal antibody, will be presented at the European Respiratory Society (ERS) International Congress 2026, held September 5-9, 2026, in Barcelona, Spain.
Pilatus Biosciences Publishes Preclinical Data in Cancer Discovery on PLT012 First-in-Class CD36-Targeting Antibody for Liver Cancer
Pilatus Biosciences, a biotechnology company developing immunometabolic therapies for cancer, today announced a preclinical publication in Cancer Discovery detailing the mechanism and therapeutic potential of its lead candidate, PLT012.
